Kura Oncology announces first US sale of KOMZIFTI, triggering $135 million payment

Kura Oncology, Inc. (NASDAQ:KURA) announced Tuesday the completion of the first US commercial sale of KOMZIFTI (ziftomenib). The transaction triggers a milestone payment of $135 million from Kyowa Kirin Co., Ltd. and Kyowa Kirin, Inc. to Kura Oncology, which the company expects to receive before the end of the year. This payment will further strengthen Kura’s financial position, with InvestingPro data showing the company already holds more cash than debt on its balance sheet and maintains a healthy current ratio of 5.12.

KOMZIFTI was approved by the US Food and Drug Administration on November 13, 2025. The payment is part of a collaboration and license agreement between Kura Oncology and Kyowa Kirin. The milestone comes as Kura’s stock has seen a remarkable 81.6% price increase over the past six months, trading at $11.44, slightly below its InvestingPro Fair Value estimate.

This information is based on a statement in a press release included in Kura Oncology’s filing with the US Securities and Exchange Commission.

In other recent news, Kura Oncology has completed its first commercial sale of KOMZIFTI, a newly approved treatment for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia. This milestone triggers a $135 million payment from their partner, Kyowa Kirin, which Kura expects to receive by the end of 2025. Additionally, KOMZIFTI has been added to the National Comprehensive Cancer Network Clinical Practice Guidelines as a Category 2A recommended treatment option, following its full FDA approval on November 13, 2025. The drug is now available through a limited network of specialty pharmacies and distributors.

Analysts have shown a positive outlook towards Kura Oncology, with Jefferies maintaining a Buy rating and emphasizing KOMZIFTI’s differentiated label and safety advantages over competitors. Jefferies noted that the drug exhibits only modest QTc prolongation compared to revumenib, which carries a Black Box warning. H.C. Wainwright also reiterated a Buy rating and set a $40.00 price target, reflecting confidence in the drug’s recent approval and partnership with Kyowa Kirin. These developments highlight Kura’s strategic progress in the oncology market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.